

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Cardboard box (100 ml)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

DORAXX 25 mg/ml solution for injection for pigs
Tulathromycin

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains:
Tulathromycin.....25 mg

3. PHARMACEUTICAL FORM

Solution for injection

4. PACKAGE SIZE

100ml

5. TARGET SPECIES

Pigs

6. INDICATION(S)

7. METHOD AND ROUTES OF ADMINISTRATION

For intramuscular use.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

Withdrawal periods:
Meat and offal: 13 days.

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

10. EXPIRY DATE

EXP {month/year}

Once opened, use within 28 days

Once opened use by...

11. SPECIAL STORAGE CONDITIONS

12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Disposal: read package leaflet.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Dopharma Research B.V.
Zalmweg 24
4941 VX Raamsdonksveer
The Netherlands

16. MARKETING AUTHORISATION NUMBER

Vm 28365/4017

17. MANUFACTURER’S BATCH NUMBER

Batch {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

Glass vial (100 ml)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

DORAXX 25 mg/ml solution for injection for pigs
Tulathromycin

2. STATEMENT OF ACTIVE SUBSTANCES

Each ml contains:
Tulathromycin.....25 mg

3. PHARMACEUTICAL FORM

Solution for injection

4. PACKAGE SIZE

100ml

5. TARGET SPECIES

Pigs

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

For intramuscular use.
Read the package leaflet before use.

8. WITHDRAWAL PERIOD(S)

Withdrawal periods:
Meat and offal: 13 days.

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use.

10. EXPIRY DATE

EXP {month/year}

Once opened, use within 28 days

Once opened use by...

11. SPECIAL STORAGE CONDITIONS

12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Dopharma Research B.V.
Zalmweg 24
4941 VX Raamsdonksveer
The Netherlands

16. MARKETING AUTHORISATION NUMBER

Vm 28365/4017

17. MANUFACTURER’S BATCH NUMBER

Batch {number}

B. PACKAGE LEAFLET

**PACKAGE LEAFLET:
DORAXX 25 mg/ml solution for injection for pigs**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER
AND OF THE MANUFACTURING AUTHORISATION HOLDER
RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder:

DOPHARMA RESEARCH B.V.
Zalmweg 24
4941 VX Raamsdonksveer
NETHERLANDS

Manufacturer responsible for batch release:

MEVET S.A.U.
Polígono Industrial El Segre, parcela 409-410
25191 Lleida
Spain

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

DORAXX 25 mg/ml solution for injection for pigs
Tulathromycin

3. STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS

Each ml contains:

Active substance:

Tulathromycin 25 mg

Excipients:

Monothioglycerol 5 mg

Clear colourless to slightly yellow solution, free from visible particles.

4. INDICATION(S)

Treatment and metaphylaxis of swine respiratory disease (SRD) associated with *Actinobacillus pleuropneumoniae*, *Pasteurella multocida*, *Mycoplasma hyopneumoniae*, *Haemophilus parasuis* and *Bordetella bronchiseptica* susceptible to tulathromycin. The presence of the disease in the group must be established before the product is used. The veterinary medicinal product should only be used if pigs are expected to develop the disease within 2–3 days.

5. CONTRAINDICATIONS

Do not use in cases of hypersensitivity to macrolide antibiotics or to any of the excipients.

6. ADVERSE REACTIONS

Pathomorphological injection site reactions (including reversible changes of congestion, oedema, fibrosis and haemorrhage) are present for approximately 30 days after injection.

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

Alternatively you can report via your national reporting system {national system details}

7. TARGET SPECIES

Pigs

8. DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION

Intramuscular use.

A single intramuscular injection of 2.5 mg tulathromycin/kg bodyweight (equivalent to 1 ml/10 kg bodyweight) in the neck.

For treatment of pigs over 40 kg bodyweight, divide the dose so that no more than 4 ml are injected at one site. The cap may be safely punctured up to 25 times.

9. ADVICE ON CORRECT ADMINISTRATION

For any respiratory disease, it is recommended to treat animals in the early stages of the disease and to evaluate the response to treatment within 48 hours after injection. If clinical signs of respiratory disease persist or increase, or if relapse occurs, treatment should be changed, using another antibiotic, and continued until clinical signs have resolved.

To ensure correct dosage bodyweight should be determined as accurately as possible to avoid underdosing. For multiple vial entry, an aspirating needle or multi-dose syringe is recommended to avoid excessive broaching of the stopper.

10. WITHDRAWAL PERIOD(S)

Meat and offal: 13 days.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.

Shelf life after first opening the container: 28 days.

12. SPECIAL WARNING(S)

Special warnings for each target species:

Cross resistance occurs with other macrolides. Do not administer simultaneously with antimicrobials with a similar mode of action such as other macrolides or lincosamides.

Special precautions for use in animals:

Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If

this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria.

Official, national and regional antimicrobial policies should be taken into account when the product is used.

Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to tulathromycin and may decrease the effectiveness of treatment with other macrolides, lincosamides and group B streptogramins, due to the potential for cross resistance.

If a hypersensitivity reaction occurs appropriate treatment should be administered without delay.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Tulathromycin is irritating to eyes. In case of accidental eye exposure, flush the eyes immediately with clean water.

Tulathromycin may cause sensitisation by skin contact resulting in e.g. reddening of the skin (erythema) and/or dermatitis. In case of accidental spillage onto skin, wash the skin immediately with soap and water.

Wash hands after use.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

If there is suspicion of a hypersensitivity reaction following accidental exposure (recognised by e.g. itching, difficulty in breathing, hives, swelling on the face, nausea,

vomiting) appropriate treatment should be administered. Seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:

Laboratory studies in rats and rabbits have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects. The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Use only according to the benefit/risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

None known.

Overdose (symptoms, emergency procedures, antidotes):

In young pigs weighing approximately 10 kg given three or five times the therapeutic dose transient signs attributed to injection site discomfort were observed and included excessive vocalisation and restlessness. Lameness was also observed when the hind leg was used as the injection site.

Incompatibilities:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Medicines should not be disposed of via wastewater or household waste. Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required. These measures should help to protect the environment.

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED


MM/YYYY

15. OTHER INFORMATION

Pack sizes:

Cardboard box with 1 vial of 100 ml.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.



Approved: 07 January 2022